Protecting blood cells during chemotherapy for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called trilaciclib, given before chemotherapy, to see if it can protect your bone marrow and help prevent dangerous drops in blood cell counts. If you have head and neck cancer that has returned or spread and haven't had prior drug treatment, this might help you stay stronger during chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have head and neck cancer that has come back or spread, and you haven't had cancer-fighting drug therapy before
- You have at least one tumor that can be measured on a scan
- You are generally well enough to care for yourself (a score of 0 or 1 on a standard scale)
- Your blood counts (like red cells, white cells, and platelets) are within a certain range
- You have not had serious heart, lung, or bleeding problems recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests a combination of two drugs, trilaciclib and immunotherapy, for people with head and neck squamous cell carcinoma that has spread or come back and can't be treated with surgery or radiation. The goal is to see if this combination helps control the cancer.
This trial tests a drug that may help protect your bone marrow during chemotherapy, possibly reducing side effects like low blood counts. It is for people with certain advanced or recurrent solid tumors who are about to start a specific chemo regimen.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This trial tests an investigational drug called trilaciclib that is given before chemoradiation to help protect your bone marrow and reduce side effects like low blood counts. It is for people with a specific type of esophageal cancer who have finished their main treatment.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy for advanced bile duct or pancreatic cancer, potentially reducing side effects like low blood counts. It aims to make chemotherapy safer and more tolerable.
Hear when a new Head and Neck Squamous Cell Carcinoma (HNSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.